Daniel Delorme
Hoofd Techniek/Wetenschap/O&O bij Neurochem (International) Ltd.
Actieve functies van Daniel Delorme
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Neurochem (International) Ltd.
Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Hoofd Techniek/Wetenschap/O&O | - | - |
Loopbaan van Daniel Delorme
Eerdere bekende functies van Daniel Delorme
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Targanta Therapeutics, Inc.
Targanta Therapeutics, Inc. BiotechnologyHealth Technology Targanta Therapeutics, Inc. develops antibiotic drugs and other related products. It focuses on developing and commercializing novel antibacterial agents to address unmet medical needs in the hospital market. The company also develops antibacterial pro-drugs for the treatment and prevention of bone infections. Targanta Therapeutics was founded in May 2007 and is located in St. Laurent, Canada | Hoofd Techniek/Wetenschap/O&O | 01-01-2003 | 01-01-2005 |
MIRATI THERAPEUTICS | Corporate Officer/Principal | 01-01-1998 | 01-01-2003 |
BELLUS HEALTH | Hoofd Techniek/Wetenschap/O&O | - | - |
Opleiding van Daniel Delorme
University of Montréal | Doctorate Degree |
Statistieken
Internationaal
Canada | 4 |
Zwitserland | 2 |
Verenigde Staten | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 1 |
Corporate Officer/Principal | 1 |
Sectoraal
Health Technology | 4 |
Commercial Services | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
BELLUS Health, Inc.
BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
Neurochem (International) Ltd.
Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Commercial Services |
Targanta Therapeutics, Inc.
Targanta Therapeutics, Inc. BiotechnologyHealth Technology Targanta Therapeutics, Inc. develops antibiotic drugs and other related products. It focuses on developing and commercializing novel antibacterial agents to address unmet medical needs in the hospital market. The company also develops antibacterial pro-drugs for the treatment and prevention of bone infections. Targanta Therapeutics was founded in May 2007 and is located in St. Laurent, Canada | Health Technology |
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
- Beurs
- Insiders
- Daniel Delorme
- Ervaring